LitCovid-sentences  

PMC:7396557 / 56903-63717 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T424 0-56 Sentence denotes Relevant Information on the Clinical Application of TRQI
T425 58-90 Sentence denotes Recommended Therapeutic Regimens
T426 91-214 Sentence denotes TRQI has been recommended in 12 therapeutic regimens of COVID-19 in China (see detailed information in Tables 1 and 2 ).
T427 216-235 Sentence denotes Ingredients of TRQI
T428 236-399 Sentence denotes Scutellaria baicalensis Georgi (Huangqin), Ursi fellis pulvis (Xiongdanfen), Forsythia suspensa (Thunb.) Vahl (Lianqiao), and Lonicera japonica Thunb. (Jinyinhua).
T429 400-467 Sentence denotes Basic information on TRQI is provided in the Supplementary Table .
T430 469-520 Sentence denotes Indications for the Treatment of COVID-19 With TRQI
T431 521-665 Sentence denotes TRQI is used for syndromes of epidemic toxin lung closure and phlegm-heat lung obstruction in the progressive stage of COVID-19 (critical case).
T432 666-784 Sentence denotes Indicative symptoms are fever, cough, cough with difficulty in expectoration, chest distress, and shortness of breath.
T433 786-830 Sentence denotes Progress of Pharmacological Research on TRQI
T434 831-1020 Sentence denotes Modern pharmacological studies have shown that TRQI is effective against influenza virus, destroys bacterial biofilm, inhibits airway inflammation, and improves lung injury (see Table 3 ).
T435 1021-1229 Sentence denotes Research by Jinsu Zheng et al. discovered that TRQI improved pathological injury of lung tissues in mice infected with influenza virus, and had significant antiviral activity in influenza virus infected mice.
T436 1230-1367 Sentence denotes The antiviral activity of TRQI might be due to its inhibition of cellular proliferation and enhancement of immunity (Zheng and Gu, 2009).
T437 1368-1503 Sentence denotes Weifeng Yang et al. discovered that TRQI could destroy methicillin-resistant Staphylococcus aureus (MRSA) biofilm and induce its death.
T438 1504-1735 Sentence denotes When combined with vancomycin or linezolid below the minimal inhibitory concentration (MIC) concentration, synergistic anti-biofilm activity was observed that was significantly higher than when using TRQI alone (Yang et al., 2018).
T439 1736-1955 Sentence denotes Research by Yi Wang et al. showed that the efficacy of TRQI in the treatment of acute pneumonia was mediated by destruction of bacterial biofilm, which is different to the mechanism of penicillin (Wang Y. et al., 2011).
T440 1956-2125 Sentence denotes Wei Liu et al. discovered that TRQI might treat airway mucus hypersecretion by regulating the interleukin-17 (IL-17) signaling pathway and its downstream protein MUC5AC.
T441 2126-2360 Sentence denotes An in vivo experiment showed that TRQI could significantly inhibit excessive secretion of LPS-stimulated MUC5AC and expression of TNF-α, interleukin-6 (IL-6), IL-8, and IL-17A in terms of protein and mRNA levels (Liu W. et al., 2019).
T442 2361-2555 Sentence denotes Animal experiments conducted by Wei Liu et al. showed that TRQI inhibited airway inflammation caused by LPS through the MAPK/NF-κB pathway, and showed a dose-dependent effect (Liu et al., 2016).
T443 2556-2798 Sentence denotes Li Wen et al. found that TRQI improved signs and symptoms in AECOPD patients, which might be mediated by reduction of serum IL-8 and neutrophil elastase (NE) levels, and improved airway inflammation and mucus hypersecretion (Li et al., 2010).
T444 2799-3128 Sentence denotes Research by Li Pengtao et al. discovered that TRQI improved blood flow in capillaries of the alveolar walls while repressing the LPS-induced inflammatory cascade, which was the pharmacological basis for its effective alleviation of acute lung injury and prevention of decreased arterial partial oxygen pressure (Li et al., 2005).
T445 3130-3155 Sentence denotes Clinical Research on TRQI
T446 3156-3454 Sentence denotes Modern clinical studies have shown that TRQI has therapeutic efficacy against infectious diseases, such as viral pneumonia, MERS, human infection with H7N9 avian influenza, acute bronchitis, acute attack of chronic bronchitis, CAP, tuberculosis accompanied by infection, and AECOPD (see Table 3 ).
T447 3455-3634 Sentence denotes TRQI has been recommended in MERS Diagnosis and Treatment Scheme (Version 2015) and Diagnosis and Treatment Scheme for Human Infection with H7N9 Avian Influenza (Version 1, 2017).
T448 3635-3924 Sentence denotes A systematic evaluation of eight published randomized and controlled trials that included a total of 590 adult patients with viral pneumonia found that TRQI had advantages in terms of response rate, faster change of chest radiography, average length of stay, and other aspects (Pan, 2016).
T449 3925-4145 Sentence denotes Research results from Jinzhi Liang et al. showed that there was no statistically significant difference in the clinical effect of combined TRQI and Ribavirin or TRQI alone in the treatment of hand-foot-and-mouth disease.
T450 4146-4224 Sentence denotes Both treatments were superior to that of Ribavirin alone (Liang et al., 2013).
T451 4225-4446 Sentence denotes Research by Wang Pei et al. showed that potential benefits of TRQI in the treatment of acute bronchitis included improved response rate, and reduced fever, cough, crackles, and X-ray shadow absorption (Wang et al., 2016).
T452 4447-4693 Sentence denotes Research results of Lini Gao et al. showed that combined use of TRQI and Western medicines was more effective than Western medicines alone in the treatment of acute bronchitis and gave superior improvement of clinical symptoms (Gao et al., 2019).
T453 4694-4882 Sentence denotes Hongli Jiang et al. showed by systematic evaluation that administration of TRQI to treat CAP on the basis of antibiotics and symptomatic treatment significantly improved clinical symptoms.
T454 4883-5078 Sentence denotes Cough with expectoration was improved, the duration of fever was shortened and recovery of chest radiography and hemogram were promoted without significant adverse reactions (Jiang et al., 2009).
T455 5079-5351 Sentence denotes Lian Xiong et al. showed by systematic evaluation that TRQI might have the same overall effect as some antibacterial drugs in treatment of patients with tuberculosis accompanied by lung infection, but improved efficacy was observed in combination with antibacterial drugs.
T456 5352-5470 Sentence denotes This might be due to the bacteriostatic effects of TRQI and elimination of inflammatory mediators (Lian et al., 2018).
T457 5471-5795 Sentence denotes A total of 14 trials and 954 patients were included in a study by Yunqing Zhong, and the results showed that combined use of TRQI and antibacterial drugs improved the clinical effects and lung function in AECOPD patients, reduced pCO2, and shortened the length of stay without serious adverse reactions (Zhong et al., 2010).
T458 5797-5821 Sentence denotes Usage and Dosage of TRQI
T459 5822-6000 Sentence denotes 20 ml once for adults, 40 ml once for severe patients, with addition of 250–500 ml 5% glucose or 0.9% sodium chloride; intravenous drip at less than 60 drops per min, once a day.
T460 6002-6027 Sentence denotes Adverse Reactions of TRQI
T461 6028-6112 Sentence denotes 1) Some patients may have dizziness, chest distress, nausea, vomiting, and diarrhea.
T462 6113-6184 Sentence denotes 2) Flushing, rash or itching and other allergic reactions occasionally.
T463 6185-6241 Sentence denotes 3) Rarely, palpitations, chill and difficulty breathing.
T464 6242-6278 Sentence denotes 4) Extremely rarely, allergic shock.
T465 6279-6379 Sentence denotes 5) Other adverse reactions: dry mouth, fever, periorbital facial edema, discomfort at infusion site.
T466 6381-6397 Sentence denotes TRQI Precautions
T467 6398-6814 Sentence denotes 1) Use is forbidden in those with liver and renal failure; 2) Use is forbidden in those with severe lung and heart disease accompanied by heart failure; 3) Use is forbidden in pregnant women and infants less than 24 months; 4) It should be used alone and must not be mixed with other drugs; 5) Dilution ratio of the liquid shall be no lower than 1:10 (liquid: solvent) and the diluted liquid must be used within 4 h.